Serum Institute of India CEO Adar Poonawalla on Wednesday said the company has restarted manufacturing of COVID-19 vaccine Covishield amid rising numbers of cases of the virus infection.
India's apex body on immunisation NTAGI has recommended administering the second dose of COVID-19 vaccine Covishield between eight and 16 weeks after the first dose.